JanOne stock, biotechnology

JanOne stock weighs revenue growth against an EPS miss

Published on 09/30/2026 at 14:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JanOne stock weighs USD 216.46 million in quarterly revenue against USD 0.05 EPS on August 4, 2026. Scotiabank raised its target to USD 33.00.

JanOne stock,  biotechnology,  life sciences,  earnings,  analyst price target,  Nasdaq, Illustration mit AI erstellt.
JanOne stock, biotechnology, life sciences, earnings, analyst price target, Nasdaq, Illustration mit AI erstellt.

JanOne stock is balancing 45.4 percent quarterly revenue growth against an earnings miss that leaves execution as the central test. The company reported USD 216.46 million in revenue for the quarter ended June 30, 2026, while diluted EPS came in at USD 0.05.

Revenue growth meets an EPS miss

According to MarketBeat on September 17, 2026, JanOne's latest quarterly revenue reached USD 216.46 million, compared with USD 203.32 million expected by analysts. The 45.4 percent year-over-year increase is the strongest operating figure in the recent report.

The earnings conversion was weaker. Quarterly EPS of USD 0.05 missed the USD 0.23 consensus estimate by USD 0.18, creating a clear gap between top-line expansion and bottom-line delivery.

Scotiabank lifts its target

Scotiabank raised its JanOne price target from USD 31.00 to USD 33.00 in a report issued on September 17, 2026, while maintaining a sector outperform rating, MarketBeat reported. The higher target contrasts with the latest EPS shortfall and places greater importance on whether revenue growth can translate into earnings.

MarketBeat also reported that Huntington initiated coverage with an outperform rating and a USD 36.00 price target on September 10, 2026. The company had set fiscal 2026 EPS guidance at USD 0.95-0.98, giving investors a defined benchmark for the next results cycle.

JanOne focuses on pain treatment

JanOne's investor relations page describes the company as a life sciences business developing treatments for diseases that cause severe pain. Its lead candidate, JAN101, targets peripheral artery disease, which the company says affects more than 8.5 million Americans.

Analyst optimism faces an earnings test

The figures create a two-sided setup: revenue growth is running ahead of the USD 203.32 million quarterly estimate, but EPS is USD 0.18 below consensus. For investors, the next material checkpoint is whether fiscal 2026 guidance of USD 0.95-0.98 remains supported by improved earnings conversion.

JanOne stock facts

  • Company: JanOne Inc.
  • Ticker: JAN
  • Primary exchange: Nasdaq
  • Sector / Industry: Life sciences and healthcare technology
  • Latest reported quarter: Q2 2026
  • Quarterly revenue: USD 216.46 million
  • Quarterly diluted EPS: USD 0.05
  • Fiscal 2026 EPS guidance: USD 0.95-0.98

Disclaimer...

en | boerse | 70204294 |